| abstract |
A pharmaceutical preparation for the treatment of diabetes mellitus comprising the following components, in percent by weight: crystalline insulin with a conventional 1 to 25.0 activity of 1 mg = 20 units additives inhibiting deactivation of insulin, 0.02 to 10.0 viz. 5-(para-[N-(3-methoxypyridazinyl-6)- sulphamido]-phenylazo)-salicylic acid, calcium gluconate or a mixture thereof preservatives 0.1 to 15.0 additives adjusting solubility of 0.01 to 10.0 insulin water-soluble polymeric base the balance. |